25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Percheron Therapeutics Limited
Buy, Hold or Sell?

Let's analyze Percheron Therapeutics Limited together

I guess you are interested in Percheron Therapeutics Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Percheron Therapeutics Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Percheron Therapeutics Limited

I send you an email if I find something interesting about Percheron Therapeutics Limited.

1. Quick Overview

1.1. Quick analysis of Percheron Therapeutics Limited (30 sec.)










1.2. What can you expect buying and holding a share of Percheron Therapeutics Limited? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
30.0%

What is your share worth?

Current worth
A$0.01
Expected worth in 1 year
A$0.01
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
A$0.00
Return On Investment
-2.7%

For what price can you sell your share?

Current Price per Share
A$0.10
Expected price per share
A$0.097 - A$0.11
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Percheron Therapeutics Limited (5 min.)




Live pricePrice per Share (EOD)
A$0.10
Intrinsic Value Per Share
A$-0.15 - A$-0.07
Total Value Per Share
A$-0.14 - A$-0.06

2.2. Growth of Percheron Therapeutics Limited (5 min.)




Is Percheron Therapeutics Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$6.3m$6.7m-$413.3k-6.5%

How much money is Percheron Therapeutics Limited making?

Current yearPrevious yearGrowGrow %
Making money-$8m-$7.6m-$363.9k-4.5%
Net Profit Margin0.0%-2,956.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Percheron Therapeutics Limited (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Percheron Therapeutics Limited?

Welcome investor! Percheron Therapeutics Limited's management wants to use your money to grow the business. In return you get a share of Percheron Therapeutics Limited.

First you should know what it really means to hold a share of Percheron Therapeutics Limited. And how you can make/lose money.

Speculation

The Price per Share of Percheron Therapeutics Limited is A$0.099. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Percheron Therapeutics Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Percheron Therapeutics Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.01. Based on the TTM, the Book Value Change Per Share is A$0.00 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Percheron Therapeutics Limited.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.01-9.0%-0.01-9.0%-0.01-8.6%-0.01-6.5%0.00-4.0%
Usd Book Value Change Per Share0.00-0.5%0.00-0.5%-0.01-8.4%0.001.0%0.000.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.00-0.5%0.00-0.5%-0.01-8.4%0.001.0%0.000.6%
Usd Price Per Share0.06-0.06-0.04-0.07-0.05-
Price to Earnings Ratio-6.43--6.43--4.67--11.17-4.79-
Price-to-Total Gains Ratio-125.10--125.10--4.76-9.73-2.81-
Price to Book Ratio8.18-8.18-5.33-12.43-11.94-
Price-to-Total Gains Ratio-125.10--125.10--4.76-9.73-2.81-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0668052
Number of shares14968
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (14968 shares)-6.8615.27
Gains per Year (14968 shares)-27.4561.06
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-27-3725951
20-55-645117112
30-82-917176173
40-110-1189235234
50-137-14512294295
60-165-17214352356
70-192-19916411417
80-220-22619470478
90-247-25321529539
100-275-28023587600

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%1.09.00.010.0%1.023.00.04.2%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%3.02.00.060.0%5.05.00.050.0%10.014.00.041.7%
Dividend per Share0.00.01.00.0%1.00.02.033.3%3.00.02.060.0%3.00.07.030.0%3.00.021.012.5%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%3.02.00.060.0%5.05.00.050.0%10.014.00.041.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Percheron Therapeutics Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.001-0.0010%-0.012+1723%0.001-147%0.001-184%
Book Value Per Share--0.0100.0100%0.011-6%0.011-8%0.008+31%
Current Ratio--2.8092.8090%4.513-38%7.880-64%7.582-63%
Debt To Asset Ratio--0.3560.3560%0.223+59%0.194+83%0.182+95%
Debt To Equity Ratio--0.5520.5520%0.287+92%0.261+112%0.237+132%
Dividend Per Share----0%-0%0.000-100%0.000-100%
Eps---0.013-0.0130%-0.013-5%-0.010-28%-0.006-56%
Free Cash Flow Per Share---0.011-0.0110%-0.009-19%-0.008-29%-0.005-59%
Free Cash Flow To Equity Per Share--0.0010.0010%-0.009+1019%0.002-50%0.001-33%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---0.074--------
Intrinsic Value_10Y_min---0.154--------
Intrinsic Value_1Y_max---0.005--------
Intrinsic Value_1Y_min---0.011--------
Intrinsic Value_3Y_max---0.017--------
Intrinsic Value_3Y_min---0.038--------
Intrinsic Value_5Y_max---0.032--------
Intrinsic Value_5Y_min---0.068--------
Market Cap89252957.376+14%76631327.04076631327.0400%53191156.416+44%87990794.342-13%66768424.477+15%
Net Profit Margin----0%-29.5640%-464.6270%-249.1400%
Operating Margin----0%-34.6690%-510.6080%-275.9380%
Operating Ratio----0%34.669-100%510.608-100%277.599-100%
Pb Ratio9.532+14%8.1848.1840%5.332+53%12.427-34%11.944-31%
Pe Ratio-7.488-16%-6.429-6.4290%-4.674-27%-11.168+74%4.795-234%
Price Per Share0.099+14%0.0850.0850%0.059+44%0.098-13%0.074+15%
Price To Free Cash Flow Ratio-8.820-16%-7.573-7.5730%-6.502-14%-13.938+84%-397.392+5148%
Price To Total Gains Ratio-145.701-16%-125.096-125.0960%-4.764-96%9.727-1386%2.806-4558%
Quick Ratio--0.0160.0160%8.223-100%10.908-100%9.402-100%
Return On Assets---0.820-0.8200%-0.886+8%-0.844+3%-0.679-17%
Return On Equity---1.273-1.2730%-1.141-10%-1.080-15%-0.871-32%
Total Gains Per Share---0.001-0.0010%-0.012+1723%0.002-145%0.001-181%
Usd Book Value--6318211.1086318211.1080%6731578.742-6%6847696.706-8%4810774.105+31%
Usd Book Value Change Per Share--0.0000.0000%-0.008+1723%0.001-147%0.001-184%
Usd Book Value Per Share--0.0070.0070%0.007-6%0.008-8%0.005+31%
Usd Dividend Per Share----0%-0%0.000-100%0.000-100%
Usd Eps---0.009-0.0090%-0.009-5%-0.006-28%-0.004-56%
Usd Free Cash Flow---6828610.933-6828610.9330%-5520282.376-19%-4846046.914-29%-2828029.240-59%
Usd Free Cash Flow Per Share---0.008-0.0080%-0.006-19%-0.005-29%-0.003-59%
Usd Free Cash Flow To Equity Per Share--0.0010.0010%-0.006+1019%0.001-50%0.001-33%
Usd Market Cap60227895.637+14%51710819.48751710819.4870%35893392.350+44%59376188.022-13%45055332.837+15%
Usd Price Per Share0.067+14%0.0570.0570%0.040+44%0.066-13%0.050+15%
Usd Profit---8043091.680-8043091.6800%-7679107.934-5%-5815498.334-28%-3528511.250-56%
Usd Revenue----0%259744.016-100%61246.198-100%369698.155-100%
Usd Total Gains Per Share--0.0000.0000%-0.008+1723%0.001-145%0.001-181%
 EOD+5 -3MRQTTM+0 -0YOY+13 -185Y+4 -2910Y+9 -24

3.3 Fundamental Score

Let's check the fundamental score of Percheron Therapeutics Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-7.488
Price to Book Ratio (EOD)Between0-19.532
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.016
Current Ratio (MRQ)Greater than12.809
Debt to Asset Ratio (MRQ)Less than10.356
Debt to Equity Ratio (MRQ)Less than10.552
Return on Equity (MRQ)Greater than0.15-1.273
Return on Assets (MRQ)Greater than0.05-0.820
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Percheron Therapeutics Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5054.209
Ma 20Greater thanMa 500.099
Ma 50Greater thanMa 1000.087
Ma 100Greater thanMa 2000.084
OpenGreater thanClose0.105
Total5/5 (100.0%)

4. In-depth Analysis

4.1 About Percheron Therapeutics Limited

Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company's product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications. Its product pipeline also includes Atesidorsen (ATL1103), an oligonucleotide targeting growth hormone receptor designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

Fundamental data was last updated by Penke on 2024-09-22 03:41:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Percheron Therapeutics Limited earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Percheron Therapeutics Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Percheron Therapeutics Limited:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-2,956.4%+2,956.4%
TTM-5Y-46,462.7%+46,462.7%
5Y-46,462.7%10Y-24,914.0%-21,548.6%
4.3.1.2. Return on Assets

Shows how efficient Percheron Therapeutics Limited is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Percheron Therapeutics Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • -82.0% Return on Assets means that Percheron Therapeutics Limited generated $-0.82 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Percheron Therapeutics Limited:

  • The MRQ is -82.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -82.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-82.0%TTM-82.0%0.0%
TTM-82.0%YOY-88.6%+6.6%
TTM-82.0%5Y-84.4%+2.4%
5Y-84.4%10Y-67.9%-16.5%
4.3.1.3. Return on Equity

Shows how efficient Percheron Therapeutics Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Percheron Therapeutics Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • -127.3% Return on Equity means Percheron Therapeutics Limited generated $-1.27 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Percheron Therapeutics Limited:

  • The MRQ is -127.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -127.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-127.3%TTM-127.3%0.0%
TTM-127.3%YOY-114.1%-13.2%
TTM-127.3%5Y-108.0%-19.3%
5Y-108.0%10Y-87.1%-20.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Percheron Therapeutics Limited.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Percheron Therapeutics Limited is operating .

  • Measures how much profit Percheron Therapeutics Limited makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Percheron Therapeutics Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Percheron Therapeutics Limited:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-3,466.9%+3,466.9%
TTM-5Y-51,060.8%+51,060.8%
5Y-51,060.8%10Y-27,593.8%-23,467.1%
4.3.2.2. Operating Ratio

Measures how efficient Percheron Therapeutics Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Percheron Therapeutics Limited:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY34.669-34.669
TTM-5Y510.608-510.608
5Y510.60810Y277.599+233.009
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Percheron Therapeutics Limited.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Percheron Therapeutics Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.81 means the company has $2.81 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Percheron Therapeutics Limited:

  • The MRQ is 2.809. The company is able to pay all its short-term debts. +1
  • The TTM is 2.809. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.809TTM2.8090.000
TTM2.809YOY4.513-1.704
TTM2.8095Y7.880-5.071
5Y7.88010Y7.582+0.298
4.4.3.2. Quick Ratio

Measures if Percheron Therapeutics Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Percheron Therapeutics Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.02 means the company can pay off $0.02 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Percheron Therapeutics Limited:

  • The MRQ is 0.016. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.016. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.016TTM0.0160.000
TTM0.016YOY8.223-8.207
TTM0.0165Y10.908-10.892
5Y10.90810Y9.402+1.506
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Percheron Therapeutics Limited.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Percheron Therapeutics Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Percheron Therapeutics Limited to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.36 means that Percheron Therapeutics Limited assets are financed with 35.6% credit (debt) and the remaining percentage (100% - 35.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Percheron Therapeutics Limited:

  • The MRQ is 0.356. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.356. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.356TTM0.3560.000
TTM0.356YOY0.223+0.132
TTM0.3565Y0.194+0.161
5Y0.19410Y0.182+0.012
4.5.4.2. Debt to Equity Ratio

Measures if Percheron Therapeutics Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Percheron Therapeutics Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 55.2% means that company has $0.55 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Percheron Therapeutics Limited:

  • The MRQ is 0.552. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.552. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.552TTM0.5520.000
TTM0.552YOY0.287+0.264
TTM0.5525Y0.261+0.291
5Y0.26110Y0.237+0.023
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Percheron Therapeutics Limited generates.

  • Above 15 is considered overpriced but always compare Percheron Therapeutics Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -6.43 means the investor is paying $-6.43 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Percheron Therapeutics Limited:

  • The EOD is -7.488. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.429. Based on the earnings, the company is expensive. -2
  • The TTM is -6.429. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.488MRQ-6.429-1.059
MRQ-6.429TTM-6.4290.000
TTM-6.429YOY-4.674-1.755
TTM-6.4295Y-11.168+4.739
5Y-11.16810Y4.795-15.963
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Percheron Therapeutics Limited:

  • The EOD is -8.820. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -7.573. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -7.573. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.820MRQ-7.573-1.247
MRQ-7.573TTM-7.5730.000
TTM-7.573YOY-6.502-1.071
TTM-7.5735Y-13.938+6.365
5Y-13.93810Y-397.392+383.455
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Percheron Therapeutics Limited is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Percheron Therapeutics Limited:

  • The EOD is 9.532. Based on the equity, the company is overpriced. -1
  • The MRQ is 8.184. Based on the equity, the company is overpriced. -1
  • The TTM is 8.184. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD9.532MRQ8.184+1.348
MRQ8.184TTM8.1840.000
TTM8.184YOY5.332+2.852
TTM8.1845Y12.427-4.242
5Y12.42710Y11.944+0.483
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Percheron Therapeutics Limited.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets14,530
Total Liabilities5,167
Total Stockholder Equity9,363
 As reported
Total Liabilities 5,167
Total Stockholder Equity+ 9,363
Total Assets = 14,530

Assets

Total Assets14,530
Total Current Assets14,473
Long-term Assets57
Total Current Assets
Cash And Cash Equivalents 11,867
Net Receivables 84
Total Current Assets  (as reported)14,473
Total Current Assets  (calculated)11,951
+/- 2,522
Long-term Assets
Property Plant Equipment 57
Long-term Assets  (as reported)57
Long-term Assets  (calculated)57
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities5,152
Long-term Liabilities15
Total Stockholder Equity9,363
Total Current Liabilities
Accounts payable 3,729
Total Current Liabilities  (as reported)5,152
Total Current Liabilities  (calculated)3,729
+/- 1,423
Long-term Liabilities
Long-term Liabilities  (as reported)15
Long-term Liabilities  (calculated)0
+/- 15
Total Stockholder Equity
Total Stockholder Equity (as reported)9,363
Total Stockholder Equity (calculated)0
+/- 9,363
Other
Capital Stock109,371
Common Stock Shares Outstanding 901,545
Net Invested Capital 9,363
Net Working Capital 9,321
Property Plant and Equipment Gross 311



5.2. Balance Sheets Structured

Currency in AUD. All numbers in thousands.

 Trend2024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-30
> Total Assets 
20,088
15,334
11,982
18,151
11,222
9,116
8,050
9,866
4,989
1,816
2,436
5,689
5,201
2,656
7,673
5,327
2,539
4,802
3,699
5,352
7,001
22,437
12,843
14,530
14,53012,84322,4377,0015,3523,6994,8022,5395,3277,6732,6565,2015,6892,4361,8164,9899,8668,0509,11611,22218,15111,98215,33420,088
   > Total Current Assets 
13,686
9,566
7,493
14,943
9,301
8,649
8,032
9,852
4,981
1,801
2,428
5,674
5,188
2,642
7,668
5,324
2,525
4,794
3,696
5,214
6,699
22,220
12,692
14,473
14,47312,69222,2206,6995,2143,6964,7942,5255,3247,6682,6425,1885,6742,4281,8014,9819,8528,0328,6499,30114,9437,4939,56613,686
       Cash And Cash Equivalents 
13,675
9,373
6,546
14,421
8,821
8,239
7,597
6,362
3,076
1,726
2,338
4,968
4,000
1,335
6,830
4,801
1,902
1,899
2,904
4,059
6,020
19,233
10,967
11,867
11,86710,96719,2336,0204,0592,9041,8991,9024,8016,8301,3354,0004,9682,3381,7263,0766,3627,5978,2398,82114,4216,5469,37313,675
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,400
0
0
0
18,416
10,500
0
010,50018,4160002,40000000000000000000
       Net Receivables 
11
53
69
222
77
92
369
3,276
1,846
17
27
624
1,013
1,168
744
420
428
331
606
689
601
1,841
1,659
84
841,6591,8416016896063314284207441,1681,01362427171,8463,2763699277222695311
       Other Current Assets 
0
140
879
300
403
318
66
214
60
58
63
82
175
140
94
103
195
164
257
257
665
533
1,467
0
01,4675336652572571641951039414017582635860214663184033008791400
   > Long-term Assets 
6,402
5,768
4,489
3,208
1,921
467
18
14
8
14
8
15
13
14
5
3
14
8
2
138
302
217
151
57
57151217302138281435141315814814184671,9213,2084,4895,7686,402
       Property Plant Equipment 
15
52
51
47
38
21
18
14
8
14
8
15
13
14
5
3
14
8
2
138
302
217
151
57
5715121730213828143514131581481418213847515215
       Intangible Assets 
6,388
5,716
4,438
3,161
1,883
446
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000004461,8833,1614,4385,7166,388
> Total Liabilities 
54
1,853
364
1,018
358
323
2,032
3,531
1,062
471
418
423
554
569
581
750
686
581
889
821
1,273
1,295
2,867
5,167
5,1672,8671,2951,2738218895816867505815695544234184711,0623,5312,0323233581,0183641,85354
   > Total Current Liabilities 
54
1,853
364
1,018
358
323
1,973
3,435
1,019
456
418
423
554
569
581
750
686
581
880
799
1,046
1,161
2,812
5,152
5,1522,8121,1611,0467998805816867505815695544234184561,0193,4351,9733233581,0183641,85354
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
50
0
0
0
2,400
113
113
79
94
94
0
09494791131132,400000500000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
50
0
0
0
0
0
0
0
0
0
0
0000000000500000000000000
       Accounts payable 
0
0
0
95
44
24
26
1,027
601
29
52
14
160
117
175
215
166
104
227
108
157
331
1,023
3,729
3,7291,0233311571082271041662151751171601452296011,02726244495000
       Other Current Liabilities 
54
50
38
924
110
299
1,947
2,409
418
427
366
409
394
402
420
535
520
477
653
691
888
829
1,789
0
01,7898298886916534775205354204023944093664274182,4091,947299110924385054
   > Long-term Liabilities 
0
0
0
0
0
0
59
95
43
15
0
0
0
0
0
0
0
0
9
23
228
134
55
15
15551342282390000000015439559000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23
227
133
48
0
048133227230000000000000000000
       Other Liabilities 
0
0
0
0
0
0
59
95
43
15
0
0
0
0
0
0
0
0
9
0
0
1
7
0
0710090000000015439559000000
> Total Stockholder Equity
20,034
13,482
11,618
17,133
10,864
8,793
6,017
6,335
3,928
1,344
2,018
5,266
4,647
2,087
7,092
4,577
1,853
4,221
2,810
4,531
5,728
21,141
9,976
9,363
9,3639,97621,1415,7284,5312,8104,2211,8534,5777,0922,0874,6475,2662,0181,3443,9286,3356,0178,79310,86417,13311,61813,48220,034
   Common Stock
20,428
19,471
23,715
33,839
33,837
37,215
39,263
41,434
41,434
42,194
44,674
49,723
51,784
52,417
56,715
56,715
57,707
62,406
63,938
69,148
77,034
98,135
98,263
0
098,26398,13577,03469,14863,93862,40657,70756,71556,71552,41751,78449,72344,67442,19441,43441,43439,26337,21533,83733,83923,71519,47120,428
   Retained Earnings -101,730-92,289-80,909-75,098-67,037-61,129-58,184-55,853-53,098-50,584-51,291-48,278-45,823-44,022-42,208-38,783-36,133-33,996-29,161-23,698-17,432-12,823-6,715-394
   Accumulated Other Comprehensive Income 
-1
-11
726
726
726
739
750
1,034
1,276
1,358
1,366
1,366
1,141
961
961
961
-178
-184
2,420
2,420
3,791
3,916
4,002
0
04,0023,9163,7912,4202,420-184-1789619619611,1411,3661,3661,3581,2761,034750739726726726-11-1
   Capital Surplus 000000000000000000000000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 
1
737
754
775
796
827
766
1,146
1,396
1,485
1,500
1,507
1,290
1,119
1,128
1,134
178
184
-2,420
2,717
3,791
3,916
4,002
0
04,0023,9163,7912,717-2,4201841781,1341,1281,1191,2901,5071,5001,4851,3961,1467668277967757547371



5.3. Balance Sheets

Currency in AUD. All numbers in thousands.




5.4. Cash Flows

Currency in AUD. All numbers in thousands.